Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) SHZ
23.84
-0.09000076(-0.38%)
Currency In CNY
- General
- Statistics
- Historical Data
- Profile
- Financials
Staidson (Beijing) BioPharmaceuticals Co., Ltd.
Address
No. 36, Jinghai Er Road
Beijing, 100176
China
Phone
86 10 6751 9888
Website
Sector
Healthcare
Industry
Biotechnology
Employees
555
First IPO Date
April 15, 2011
Key Executives
| Name | Title | Pay | Year Born |
| Shicheng Li | Head of Accounting & Financial Director | 0 | 1982 |
| Maorong Yu | Secretary of the Board & Deputy GM | 0 | 1981 |
| Wang Chao | General Manager | 0 | 1982 |
Description
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
